AT350383T - Synthesis of epothilones, intermediates for analogs and their uses - Google Patents

Synthesis of epothilones, intermediates for analogs and their uses

Info

Publication number
AT350383T
AT350383T AT03793304T AT03793304T AT350383T AT 350383 T AT350383 T AT 350383T AT 03793304 T AT03793304 T AT 03793304T AT 03793304 T AT03793304 T AT 03793304T AT 350383 T AT350383 T AT 350383T
Authority
AT
Austria
Prior art keywords
epothilones
analogs
intermediates
synthesis
uses
Prior art date
Application number
AT03793304T
Other languages
German (de)
Inventor
Samuel J Danishefsky
Alexey Rivkin
Fumihiko Yoshimura
Ortega Ana Esther Gabarda
Young Shin Cho
Ting-Chao Chou
Huajin Dong
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US40582302P priority Critical
Priority to US40858902P priority
Priority to US42312902P priority
Priority to US45615903P priority
Priority to US10/402,004 priority patent/US6921769B2/en
Priority to US10/435,408 priority patent/US7649006B2/en
Priority to US49674103P priority
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of AT350383T publication Critical patent/AT350383T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
AT03793304T 2002-08-23 2003-08-22 Synthesis of epothilones, intermediates for analogs and their uses AT350383T (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US40582302P true 2002-08-23 2002-08-23
US40858902P true 2002-09-06 2002-09-06
US42312902P true 2002-11-01 2002-11-01
US45615903P true 2003-03-20 2003-03-20
US10/402,004 US6921769B2 (en) 2002-08-23 2003-03-28 Synthesis of epothilones, intermediates thereto and analogues thereof
US10/435,408 US7649006B2 (en) 2002-08-23 2003-05-09 Synthesis of epothilones, intermediates thereto and analogues thereof
US49674103P true 2003-08-21 2003-08-21

Publications (1)

Publication Number Publication Date
AT350383T true AT350383T (en) 2007-01-15

Family

ID=31950966

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03793304T AT350383T (en) 2002-08-23 2003-08-22 Synthesis of epothilones, intermediates for analogs and their uses
AT06026750T AT450534T (en) 2002-08-23 2003-08-22 Synthesis of epothilones, intermediates thereof, analogs and their use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06026750T AT450534T (en) 2002-08-23 2003-08-22 Synthesis of epothilones, intermediates thereof, analogs and their use

Country Status (18)

Country Link
US (1) US7875638B2 (en)
EP (3) EP1506203B1 (en)
JP (2) JP4791183B2 (en)
KR (1) KR101173510B1 (en)
CN (2) CN102532120A (en)
AT (2) AT350383T (en)
AU (1) AU2003260002B2 (en)
CA (1) CA2496477C (en)
DE (2) DE60330407D1 (en)
DK (2) DK1767535T3 (en)
ES (2) ES2281692T3 (en)
IL (1) IL167046A (en)
MX (1) MXPA05002113A (en)
NZ (1) NZ538522A (en)
PH (1) PH12012501351A1 (en)
PT (2) PT1506203E (en)
SI (1) SI1767535T1 (en)
WO (1) WO2004018478A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
EP1506203B1 (en) 2002-08-23 2007-01-03 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CA2539801A1 (en) * 2003-10-09 2005-04-21 Kosan Biosciences, Inc. Therapeutic formulations
AU2003264822A1 (en) * 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
US20040152708A1 (en) * 2002-11-07 2004-08-05 Yong Li Trans-9,10-dehydroepothilone C and D, analogs thereof and methods of making the same
PT1805192E (en) 2004-10-25 2013-01-23 Dekk Tec Inc Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
US7238816B2 (en) * 2005-04-21 2007-07-03 Hoffmann-La Roche Inc. Preparation of epothilone derivatives
EP2118079A1 (en) 2007-02-07 2009-11-18 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Synthetic macrocyclic compounds for treating cancer
EP2155682B1 (en) 2007-04-06 2015-06-24 Ziopharm Oncology, Inc. Salts of isophosphoramide mustard and analogs thereof
WO2008141130A1 (en) * 2007-05-11 2008-11-20 Kosan Biosciences, Inc. Process for the preparation of epothilones
WO2009112077A1 (en) * 2008-03-13 2009-09-17 F. Hoffmann-La Roche Ag Process for the preparation of epothilone precursor compounds
AU2009276512B2 (en) 2008-07-31 2014-12-18 Ziopharm Oncology, Inc. Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
AU2010218109B2 (en) 2009-02-24 2015-04-09 Dekk-Tec, Inc. Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
WO2010138686A1 (en) 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
CN101747326B (en) * 2010-01-12 2012-07-25 山东大学 18-macrolide epothilone compound and application thereof
AU2011224241B2 (en) 2010-03-10 2014-05-08 Sri International The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
WO2012033601A1 (en) 2010-08-20 2012-03-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Thiosemicarbazones with mdr1 - inverse activity
JP6130495B2 (en) 2012-05-25 2017-05-17 アメリカ合衆国 Method of modulating cannabinoid receptor activity-related disorders and diseases
CN106470705A (en) 2014-08-08 2017-03-01 美国政府(由卫生和人类服务部的部长所代表) Photo-controlled removal of targets in vitro and in vivo
WO2019099615A1 (en) 2017-11-17 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605661A (en) * 1984-06-18 1986-08-12 Eli Lilly And Company Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles
EP0225292A3 (en) 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
DE3811574A1 (en) * 1988-03-31 1989-10-19 Schering Ag N-substituted imidazole, processes for their manufacture and their use in medicinal products
DE4138042C2 (en) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilones, their method of preparation as well as agents containing these compounds
EP0797988B1 (en) 1993-07-19 2009-01-14 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US20030203976A1 (en) 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
DK0903348T4 (en) 1995-11-17 2008-10-20 Biotechnolog Forschung Gmbh Epothilone derivatives and their preparation
DE19607702A1 (en) 1996-02-29 1997-09-04 Biotechnolog Forschung Gmbh Heterocycles, manufacturing methods and means
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
EP1683520B1 (en) 1996-03-12 2013-11-20 PG-TXL Company, L.P. Water-soluble prodrugs
US20040106985A1 (en) 1996-04-26 2004-06-03 Jang G. David Intravascular stent
US5917084A (en) 1996-07-03 1999-06-29 Millennium Pharmaceuticals, Inc. Antifungal agents
DE19645361A1 (en) 1996-08-30 1998-04-30 Ciba Geigy Ag Production of epothilone compounds with taxol-like activity
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DE19636343C1 (en) 1996-08-30 1997-10-23 Schering Ag New (di:methyl)-dioxanyl-methyl-pentanone and related compounds
DE19638870B4 (en) 1996-09-23 2009-05-14 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysins, processes for their production and agents containing them
DE19645362A1 (en) 1996-10-28 1998-04-30 Ciba Geigy Ag Production of epothilone compounds with taxol-like activity
AU753546B2 (en) * 1996-11-18 2002-10-24 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Epothilone C, D, E and F, production process, and their use as cytostatic as well as phytosanitary agents
JP4579351B2 (en) 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ Synthesis and intermediates and the like, as well as its use of epothilone
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20020058286A1 (en) 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6660758B1 (en) 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (en) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr New beta-keto-alcohol derivatives
CN1544436A (en) 1997-02-25 2004-11-10 生物技术研究有限公司(Gbf) Process for the preparation of epothilone a and b n-oxides and the products obtained thereby
US20020086812A1 (en) 1997-03-04 2002-07-04 Schweinfest Clifford W. Methods and compositions for diagnosis and treatment of cancer
DE19713970B4 (en) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone synthesis building blocks II - Prenylderivate
AT225783T (en) 1997-04-18 2002-10-15 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as a reaction medium
DE19849464A1 (en) 1997-04-30 2000-04-27 Schering Ag Stent with polymeric coating having pockets, preferably cyclodextrin stuctures, containing active agent for prophylaxis of restenosis
US6303767B1 (en) 1998-11-05 2001-10-16 Kosan Biosciences, Inc. Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis
DE19821954A1 (en) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Preparation of epothilone derivatives
DE19720312A1 (en) 1997-05-15 1998-11-19 Hoechst Ag Preparation with increased in vivo compatibility
US20030049841A1 (en) 1997-06-16 2003-03-13 Short Jay M. High throughput or capillary-based screening for a bioactivity or biomolecule
DE19726627A1 (en) 1997-06-17 1998-12-24 Schering Ag New intermediates for epothilone
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DE19833750A1 (en) 1997-07-16 1999-02-25 Schering Ag New thiazolyl-alkadienol and -epoxide derivatives
DE19735574A1 (en) 1997-08-09 1999-02-11 Schering Ag New 3-hydroxy-5-oxo-hexanoic acid derivatives
DE19735578A1 (en) 1997-08-09 1999-02-11 Schering Ag New di:hydroxy-hexanone or -pentene derivatives
DE19735575A1 (en) 1997-08-09 1999-02-11 Schering Ag New di:hydroxy-butanal or -pentene derivatives
AT368036T (en) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag New epothilone derivatives, methods for their preparation and their pharmaceutical use
DE19744135C1 (en) 1997-09-29 1999-03-25 Schering Ag Medical implants coated with epothilone
DE19749717A1 (en) 1997-10-31 1999-05-06 Schering Ag New epothilone derivatives
DE19751200A1 (en) 1997-11-13 1999-05-20 Schering Ag New epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6280999B1 (en) 1998-01-23 2001-08-28 Kosan Bioscience Sorangium polyketide synthases and encoding DNA therefor
US6090601A (en) 1998-01-23 2000-07-18 Kosan Bioscience Sorangium polyketide synthase
SK287775B6 (en) 1998-02-05 2011-09-05 Novartis Ag Pharmaceutical formulation containing epothilone, infusion solution and use of pharmaceutical formulation
DE19804673A1 (en) 1998-02-06 1999-08-12 Studiengesellschaft Kohle Mbh Process for preparing macrocyclic products by ring-closing metathesis Deen
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
AT307123T (en) 1998-02-25 2005-11-15 Sloan Kettering Inst Cancer Synthesis of epothilones, their intermediates and analog connections
FR2775187B1 (en) 1998-02-25 2003-02-21 Novartis Ag Use of epothilone B for the manufacture of a pharmaceutical preparation antiproliferative and a composition comprising epothilone B as an antiproliferative agent in vivo
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
DE19813821A1 (en) 1998-03-20 1999-09-23 Schering Ag New epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
JPH11322611A (en) * 1998-05-14 1999-11-24 Sankyo Co Ltd Antiviral agent
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
DE19826988A1 (en) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilone secondary components
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
DE19830060A1 (en) 1998-06-30 2000-02-10 Schering Ag New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis
US6221641B1 (en) 1998-07-02 2001-04-24 Leland Stanford Junior University Method for making polyketides
US20030199535A1 (en) 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
DE69934242T2 (en) 1998-10-02 2007-09-20 Kosan Biosciences, Inc., Hayward Polyketide synthase enzyme, and recombinant DNA constructs for the production of related FK-506 and FK-520 compounds
DE19846493A1 (en) 1998-10-09 2000-04-13 Biotechnolog Forschung Gmbh DNA sequence coding for products involved in the biosynthesis of polyketide or heteropolyketide compounds, especially epothilone
DE19848306A1 (en) 1998-10-14 2000-04-20 Schering Ag High yield preparation of cytotoxic or fungicidal compound epothilon B, from phenylsulfonyl-butanol derivative by multistage process via new thiazole derivative intermediates
JP2003512013A (en) 1998-10-29 2003-04-02 コーサン バイオサイエンシーズ, インコーポレイテッド Recombinant oleandolide polyketide synthases
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
EP1140944B1 (en) 1998-12-22 2003-08-27 Novartis AG Epothilone derivatives and their use as antitumor agents
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
DE19908760A1 (en) 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable epothilon derivatives having modified macrocyclic ring, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
DE50014587D1 (en) 1999-02-18 2007-10-04 Bayer Schering Pharma Ag 16-halo-epothilone derivatives, to processes for their preparation and their pharmaceutical use
US6538038B1 (en) 1999-02-18 2003-03-25 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
US6406722B1 (en) 1999-02-18 2002-06-18 Robert G. Gallaher Method of treating viral infections and lesions with taxane compounds
DE19908765A1 (en) 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable 16-halo or cyano-epothilone derivatives are cell division regulators useful e.g. for treating malignant tumors or chronic inflammatory disease
DE19908767A1 (en) 1999-02-18 2000-10-19 Schering Ag New stable, modified epothilone derivatives, are cell division regulators useful for treating malignant tumors, angiogenesis or chronic inflammatory disease
DE19908763A1 (en) 1999-02-18 2000-08-24 Schering Ag New, chemically and metabolically stable benzo-fused epothilon derivatives, useful e.g. for treating malignant tumors or chronic inflammatory disease, are cell division regulators
DE19907588A1 (en) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh New C-21 modified epothilone derivatives useful for treating e.g. cancer and other proliferative diseases and inhibiting angiogenesis and inducing apoptosis
WO2000050423A1 (en) 1999-02-22 2000-08-31 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modified epothilones
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
US6603015B2 (en) 1999-03-29 2003-08-05 University Of Kansas Synthesis of epothilones
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
AT275177T (en) 1999-04-06 2004-09-15 Seiko Epson Corp The ink composition containing a copper complex dye
JP2002541200A (en) 1999-04-14 2002-12-03 デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド Methods and compositions for the treatment of cancer
ID30460A (en) 1999-04-15 2001-12-06 Squibb Bristol Myers Co Cyclic inhibitors of protein tyrosine kinase
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
JP4707240B2 (en) * 1999-05-05 2011-06-22 アベンティス・フアーマ・リミテッド Urea as a cell adhesion modulating agent
DE19923001A1 (en) 1999-05-13 2000-11-16 Schering Ag New epothilone derivatives, used as mitosis regulators e.g. for treating malignant tumors, psoriasis or arthritis
DE19930111A1 (en) 1999-07-01 2001-01-04 Biotechnolog Forschung Gmbh New C-21 modified epothilone derivatives useful for treating e.g. cancer and other proliferative diseases and inhibiting angiogenesis and inducing apoptosis
KR100621185B1 (en) 1999-09-09 2006-09-06 삼성전자주식회사 A micro-computer of a operation recoding type in a DDC monitor and control method thereof
US20020147197A1 (en) 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
US20030054977A1 (en) 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US20020045220A1 (en) 1999-10-13 2002-04-18 Chaitan Khosla Biosynthesis of polyketide synthase substrates
DE19954230A1 (en) 1999-11-04 2001-11-15 Schering Ag New, chemically and metabolically stable 16-halo or cyano-epothilone derivatives are cell division regulators useful e.g. for treating malignant tumors or chronic inflammatory disease
DE19954228A1 (en) 1999-11-04 2001-09-13 Schering Ag New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis
CN1086389C (en) * 1999-11-12 2002-06-19 中国科学院上海有机化学研究所 Isoesperamicin and its synthesizing process
US6596875B2 (en) * 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
US6906188B2 (en) 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
EP1259490A2 (en) 2000-03-01 2002-11-27 Sloan Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20030004338A1 (en) 2001-02-01 2003-01-02 Li Wen Sen Process for the preparation of epothilone analogs
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
DE10015836A1 (en) 2000-03-27 2001-10-11 Schering Ag New epothilone derivatives used for treating e.g. malignant melanoma, breast carcinoma, psoriasis, multiple sclerosis and arthritis
TWI310684B (en) 2000-03-27 2009-06-11 Squibb Bristol Myers Co Synergistic pharmaceutical kits for treating cancer
DE10020517A1 (en) 2000-04-19 2001-10-25 Schering Ag New 13-halo or cyano-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
DE10020899A1 (en) 2000-04-20 2001-10-25 Schering Ag New 9-oxa-epothilone derivatives, are phase-specific cell division regulators useful for treating malignant tumors, angiogenesis or inflammatory disease
EP1278882A4 (en) 2000-05-02 2004-08-18 Kosan Biosciences Inc Overproduction hosts for biosynthesis of polyketides
AU6658301A (en) 2000-05-26 2001-12-11 Kosan Biosciences Inc Epothilone derivatives and methods for making and using the same
CA2417358A1 (en) 2000-08-09 2002-02-14 Daniel V. Santi Bio-intermediates for use in the chemical synthesis of polyketides
WO2002008440A2 (en) 2000-07-25 2002-01-31 Kosan Biosciences, Inc. Fermentation process for epothilones
PT1309597E (en) 2000-08-16 2007-08-22 Squibb Bristol Myers Co Polymorphs of an epothilone analog
US6569842B2 (en) * 2000-08-18 2003-05-27 Board Of Trustees Of The University Of Illinois, The Method of preparing and use of prodrugs of betulinic acid derivatives
US7766956B2 (en) 2000-09-22 2010-08-03 Boston Scientific Scimed, Inc. Intravascular stent and assembly
WO2002030356A2 (en) 2000-10-13 2002-04-18 The University Of Mississipi Synthesis of epothilones and relates analogs
DE50111753D1 (en) 2000-10-16 2007-02-08 R & D Biopharmaceuticals Epothilone synthesis components i: asymmetrically substituted acyloins and acyloinderivate, processes for their preparation and their use for the production of epothilones and epothilone derivatives
DE10051136A1 (en) 2000-10-16 2002-04-18 Ludger A Wessjohann New alpha-hydroxy-ketone derivatives, useful as intermediates for biologically active polyketides, terpenoids, epothilones and their derivatives
US20020169135A1 (en) 2000-11-07 2002-11-14 Pardee Arthur B. Method of treating hematologic tumors and cancers
US7070797B2 (en) 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
AU2187302A (en) 2000-11-22 2002-06-03 Novartis Ag Epothilone resistant cell lines
GB0029895D0 (en) * 2000-12-07 2001-01-24 Novartis Ag Organic compounds
CZ20032022A3 (en) 2001-01-25 2004-04-14 Bristol-Myers Squibb Company Parenteral formulation containing epothilone analogs
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
NZ526870A (en) 2001-01-25 2005-11-25 Squibb Bristol Myers Co Methods of administering epothilone analogs for the treatment of cancer
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
KR20040025895A (en) 2001-02-20 2004-03-26 브리스톨-마이어스스퀴브컴파니 Treatment of refractory tumors using epothilone derivatives
BR0207316A (en) 2001-02-20 2004-02-10 Squibb Bristol Myers Co epothilone derivatives for the treatment of refractory tumors
NZ527557A (en) 2001-02-27 2005-05-27 Biotechnolog Forschung Gmbh Degradation of epothilones and ethynyl substituted epothilones
AT434438T (en) 2001-02-27 2009-07-15 Novartis Pharma Gmbh Combination comprising an inhibitor of the signal transduction and an epothilone derivative
RU2321400C2 (en) 2001-03-14 2008-04-10 Бристол-Маерс Сквибб Компани Epotilone analogue composition in combination with chemotherapeutic agents for cancer treatment
EP1372650B1 (en) 2001-03-19 2008-11-19 Novartis AG Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
US20020169125A1 (en) 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
IL157993D0 (en) 2001-03-23 2004-03-28 Napro Biotherapeutics Inc Molecular conjugates for use in cancer treatment and methods for the preparation thereof
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
EP1610751A4 (en) 2001-04-26 2006-05-24 Univ Texas Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US20030023082A1 (en) 2001-05-15 2003-01-30 Gary Ashley Epothilone derivatives and methods for making and using the same
CA2449077A1 (en) 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives
CN1543356B (en) 2001-06-25 2011-09-28 味之素株式会社 Anti-tumor agent
DE10138347A1 (en) 2001-08-03 2003-02-27 Schering Ag Protected-3,5-dihydroxy-2,2-dimethyl-valeronitrile for the synthesis of Epothilonen- and derivatives and methods for preparing
US6933385B2 (en) 2001-08-03 2005-08-23 Schering Ag Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
AT409473T (en) 2001-08-23 2008-10-15 Novartis Pharma Gmbh Cyclopropyl and cyclobutyl epothilone analog
SK1102004A3 (en) 2001-08-31 2005-05-05 Bristol-Myers Squibb Company Medicament for the treatment of proliferative diseases and pharmaceutical composition for the treatment of the cancer
WO2003022844A2 (en) * 2001-09-06 2003-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones intermediates thereto and analogues thereof
DK1423381T3 (en) 2001-09-06 2007-05-07 Schering Corp 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen-dependent diseases
US20040058899A1 (en) 2002-09-25 2004-03-25 Klimko Peter G. Use of epothilones and analogs in conjunction with ophthalmic surgery
WO2003029195A1 (en) 2001-09-28 2003-04-10 Sumika Fine Chemicals Co., Ltd. Intermediates for epothilone derivative and process for producing these
TW200300350A (en) 2001-11-14 2003-06-01 Squibb Bristol Myers Co C-5 modified indazolylpyrrolotriazines
US20030134883A1 (en) 2001-11-26 2003-07-17 David Myles 14-Methyl-epothilones
AU2002346644A1 (en) 2001-12-03 2003-06-17 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
CA2549463A1 (en) 2002-12-12 2004-07-01 Conforma Therapeutics Corporation Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
DE10164592A1 (en) 2001-12-21 2003-07-03 Schering Ag C1-C6-epothilone fragments and procedures for the preparation of C1-C6-fragments of epothilones and derivatives thereof
US6884608B2 (en) 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
TW200303202A (en) 2002-02-15 2003-09-01 Squibb Bristol Myers Co Method of preparation of 21-amino epothilone derivatives
EP1340498A1 (en) 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
AU2003212457A1 (en) 2002-03-01 2003-09-16 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
CA2478087A1 (en) 2002-03-07 2003-09-18 The Board Of Trustees Of The University Of Illinois Microtubule stabilizing compounds
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
SI1483251T1 (en) 2002-03-12 2010-03-31 Squibb Bristol Myers Co C3-cyano epothilone derivatives
US6900208B2 (en) 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
TW200400191A (en) 2002-05-15 2004-01-01 Squibb Bristol Myers Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
JP2006514681A (en) 2002-05-20 2006-05-11 コーザン バイオサイエンシス インコーポレイテッド Method of administration of epothilone d
AU2003243561A1 (en) 2002-06-14 2003-12-31 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TW200401638A (en) 2002-06-20 2004-02-01 Squibb Bristol Myers Co Heterocyclic inhibitors of kinases
EP1530456A2 (en) 2002-08-23 2005-05-18 Munich Biotech AG Non-vesicular cationic lipid formulations
DE10232094A1 (en) 2002-07-15 2004-02-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 5-and 15-disubstituted epothilones Thiaepothilone
TWI329112B (en) 2002-07-19 2010-08-21 Squibb Bristol Myers Co Novel inhibitors of kinases
KR20050026033A (en) 2002-07-31 2005-03-14 쉐링 악티엔게젤샤프트 New effector conjugates, process for their production and their pharmaceutical use
US6951859B2 (en) 2002-08-02 2005-10-04 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
AT381569T (en) 2002-08-02 2008-01-15 Novartis Pharma Gmbh epothilone
US20030036177A1 (en) 2002-08-13 2003-02-20 Joachim Strohhacker Single colonies of myxobacteria cells
AU2003260723A1 (en) 2002-08-17 2004-03-03 The Queens Universlty Of Belfast Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US20040247620A1 (en) 2002-08-21 2004-12-09 Kosan Biosciences, Inc. Transformation system based on the integrase gene and attachment site for Myxococcus xanthus bacteriophage Mx9
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1506203B1 (en) 2002-08-23 2007-01-03 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
WO2004022559A1 (en) 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA05002570A (en) 2002-09-04 2005-09-08 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors.
TW200412966A (en) 2002-09-04 2004-08-01 Schering Corp Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20040043089A1 (en) 2002-09-04 2004-03-04 Rabie A-Bakr M Buguzhi agent and composition and methods of preparing and administering the same
AR041133A1 (en) 2002-09-04 2005-05-04 Pharmacopeia Drug Discovery Pyrazolopyrimidines as inhibitors of cyclin dependent kinase
GB0221312D0 (en) 2002-09-13 2002-10-23 Novartis Ag Organic compounds
JP2005538740A (en) 2002-09-16 2005-12-22 アグサート・インターナショナル・エルエルシー Food-borne pathogens and spoilage detection apparatus and method
CN100475812C (en) 2002-09-19 2009-04-08 先灵公司 Pyrazolopyridines as cyclin dependent kinase inhibitors
JP4845379B2 (en) 2002-09-19 2011-12-28 シェーリング コーポレイションSchering Corporation Imidazopyridine as cyclin-dependent kinase inhibitor
DE10244847A1 (en) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck A medical device for drug delivery
TW200412967A (en) 2002-09-23 2004-08-01 Schering Corp Novel imidazopyrazines as cyclin dependent kinase inhibitors
KR20050057520A (en) 2002-09-23 2005-06-16 쉐링 코포레이션 Imidazopyrazines as cyclin dependent kinase inhibitors
MXPA05003006A (en) 2002-09-23 2005-06-22 Squibb Bristol Myers Co Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b.
EP1545529A4 (en) 2002-09-30 2010-03-03 Squibb Bristol Myers Co Novel tyrosine kinase inhibitors
TW200501960A (en) 2002-10-02 2005-01-16 Squibb Bristol Myers Co Synergistic kits and compositions for treating cancer
CN1297258C (en) 2002-10-09 2007-01-31 高山生物科学股份有限公司 EPO D+5-fu/gemcitabine
JP2006504743A (en) 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド Therapeutic formulation
AU2003264822A1 (en) 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
CN1297269C (en) 2002-10-15 2007-01-31 路易斯安那州州立大学及农业机械学院管理委员会 Use of epothilone derivatives for the treatment of hyperparathyroidism
WO2004043363A2 (en) 2002-11-06 2004-05-27 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
US20040152708A1 (en) 2002-11-07 2004-08-05 Yong Li Trans-9,10-dehydroepothilone C and D, analogs thereof and methods of making the same
TW200418508A (en) 2002-11-14 2004-10-01 Newbiotics Inc Peptide deformylase activated prodrugs
ES2330517T3 (en) 2002-11-28 2009-12-11 Wolfgang Richter Tia-epothilone derivatives for the treatment of cancer.
CA2508536A1 (en) 2002-12-04 2004-06-17 Technologies Biolactis Inc. An exopolysaccharides delivery system for active molecules
JP2006510626A (en) 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト Epothilone analogs for site-specific supply in the process of proliferative diseases
DE10256982A1 (en) 2002-12-05 2004-06-24 Schering Ag New epithilone derivatives are useful for the treatment of diseases associated with proliferative diseases e.g. tumor diseases, inflammatory diseases and neurodegenerative diseases
KR20140027554A (en) 2002-12-09 2014-03-06 아브락시스 바이오사이언스, 엘엘씨 Compositions and methods of delivery of pharmacological agents
EP1575454A4 (en) 2002-12-09 2006-11-29 Medtronic Vascular Inc Modular stent having polymer bridges at modular unit contact sites
CA2510610A1 (en) 2002-12-09 2004-06-24 Novartis Ag Microtubule stabilisers for treating stenosis in stents
TW200420565A (en) 2002-12-13 2004-10-16 Squibb Bristol Myers Co C-6 modified indazolylpyrrolotriazines
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
GB0230024D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
US7189716B2 (en) 2003-01-03 2007-03-13 Bristol-Myers Squibb Company Tyrosine kinase inhibitors
AU2003219947A1 (en) 2003-02-26 2004-09-28 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
GB0305928D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
BRPI0408891A (en) 2003-03-28 2006-04-11 Kosan Biosciences Inc devices, methods and compositions for preventing restenosis

Also Published As

Publication number Publication date
DK1506203T3 (en) 2007-05-14
PH12012501351A1 (en) 2014-10-13
ES2281692T3 (en) 2007-10-01
CA2496477C (en) 2012-10-16
MXPA05002113A (en) 2005-06-03
AT450534T (en) 2009-12-15
KR101173510B1 (en) 2012-08-21
CN1759115A (en) 2006-04-12
SI1767535T1 (en) 2010-03-31
US7875638B2 (en) 2011-01-25
EP1767535B1 (en) 2009-12-02
JP2006502246A (en) 2006-01-19
WO2004018478A3 (en) 2004-12-09
PT1767535E (en) 2010-02-24
US20090149516A1 (en) 2009-06-11
KR20050083652A (en) 2005-08-26
JP4791183B2 (en) 2011-10-12
DE60310916T2 (en) 2007-11-15
EP2186811A1 (en) 2010-05-19
WO2004018478A2 (en) 2004-03-04
PT1506203E (en) 2007-04-30
AU2003260002B2 (en) 2010-03-18
EP1767535A1 (en) 2007-03-28
CN102532120A (en) 2012-07-04
JP2011195589A (en) 2011-10-06
EP1506203B1 (en) 2007-01-03
IL167046A (en) 2012-06-28
EP1506203A2 (en) 2005-02-16
NZ538522A (en) 2008-03-28
CA2496477A1 (en) 2004-03-04
AU2003260002A1 (en) 2004-03-11
DK1767535T3 (en) 2010-04-12
DE60310916D1 (en) 2007-02-15
DE60330407D1 (en) 2010-01-14
ES2336937T3 (en) 2010-04-19

Similar Documents

Publication Publication Date Title
DE60305333D1 (en) Printing process and lötmaskenfarbstoffzusammensetzung
DE60237196D1 (en) Piezoelectric charged droplet source
DE50208033D1 (en) Synergistic mixtures of 1,2-alkanediols
IS8401A (en) Fully human antibodies against human 4-1BB (CD137)
IS7524A (en) Históndeasetýlasahemlar
AT545630T (en) Crystalline form of the potassium salt of (2R, 4R) -monatin and sweet composition containing them
DE602004030584D1 (en) Production of olefins
AT331455T (en) Mechanism for deflection of support surfaces
AT521612T (en) Synthesis of boronsäureester- and boronic acid compounds
NO330755B1 (en) Compounds, pharmaceutical compositions and uses thereof
AT401727T (en) Presence and message-system to maintain information and to communicate
IS2884B (en) Kínasólínafleiður
DE60122528D1 (en) Synthesis of molecular sieve catalysts
DE50313324D1 (en) disubstituted pyrazolylcarboxanilides
DE69927790D1 (en) Synthesis of epothilones, their intermediates and analog connections
DE602004014008D1 (en) For resolution of integer carrier phase-ambiguities
AT477053T (en) Tetramerization of olefins
AT533743T (en) Urea derivatives of aminotetralin as modulators of the vanilloid receptor vr1
AT441650T (en) Spirocyclic cyclohexane derivatives
DE60319443D1 (en) Assembly of surgical stapling tool
AT442359T (en) Crystalline forms of (R) -8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-be zazepinhydrochlorid
DE60313872D1 (en) Pyrazoloä1,5-aüpyrimidine as inhibitors of cyclin-dependent kinases-
AT416168T (en) Modulators of the vanilloid
DE60331172D1 (en) Synthesis of carbon nanotubes from metallic and ethinyl compounds
NO20161918A1 (en) Compositions for transdermal oksybutyninterapi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1506203

Country of ref document: EP